Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lilly/Amylin Look To Limit Byetta Access Due To Cartridge Shortage

This article was originally published in The Pink Sheet Daily

Executive Summary

Exenatide supplies for patients already on the therapy will be maintained, Lilly said.

You may also be interested in...



Byetta Shortage Is Bygone Era

After backfilling the supply channel using contract manufacturers, Lilly/Amylin resume promotions for the injectable type 2 diabetes product.

Byetta Shortage Is Bygone Era

After backfilling the supply channel using contract manufacturers, Lilly/Amylin resume promotions for the injectable type 2 diabetes product.

Nastech/Amylin’s Exenatide Nasal Spray Deal Could Be Shot In The Arm For Lilly

Lilly, which markets injectable exenatide, may inherit commercialization rights to the nasal spray formulation if Nastech/Amylin’s development proves successful.

Related Content

Topics

UsernamePublicRestriction

Register

MT125529

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel